Phoenix Life Sciences International Limited

PLSI

US71910Q1022

Phoenix Life Sciences International Limited Reports Earnings Results for the Full Year Ended February 28, 2019

April 10, 2020 at 06:04 am EDT

Phoenix Life Sciences International Limited announced earnings results for the full year ended February 28, 2019. For the full year, the company announced net loss was USD 3.117 million compared to USD 76,590 a year ago. Basic loss per share was USD 0.27 compared to USD 2.46 a year ago.

Latest news about Phoenix Life Sciences International Limited

ArCare Holdings Sdn Bhd entered into letter of intent to acquire Phoenix Life Sciences International Limited.	21-12-23	CI
Phoenix Life Sciences International Limited cancelled the transaction announced on April 30, 2019	20-04-29	CI
Phoenix Life Sciences International Limited Reports Earnings Results for the Full Year Ended February 28, 2019	20-04-10	CI
Phoenix Life Sciences International Limited Announces Management Changes	19-08-29	CI
Phoenix Life Sciences International Limited Announces Resignation of Michael Gobel from His Role as Director	19-08-09	CI
Phoenix Life Sciences International Limited Announces Management Changes	19-07-11	CI
Phoenix Life Sciences International Limited Announces Management Changes	19-06-28	CI
Phoenix Life Sciences International Limited Signs Exclusive Agreement with Vanuatu Government for 25-Year Diabetes Management Program and Global Medical Cannabis Export License	19-06-04	CI
Phoenix Life Sciences International Limited Names Maturine Carlot-Tary as Director of Health and Nutrition	19-05-17	CI
Phoenix Life Sciences International Limited announced that it expects to receive $40 million in funding	19-04-29	CI
Phoenix Life Sciences International Limited Appoints John Taleo as Global Head of Security	19-04-16	CI
Phoenix Life Sciences International Limited announced that it has received $0.879685 million in funding	19-04-10	CI
Phoenix Life Sciences International Limited Appoints Tekon Timothy Tumukon as Head of Biosecurity Services	19-04-08	CI
Phoenix Life Sciences International Limited Appoints Santus Wari as Head of National Healthcare of the Company	19-03-28	CI
Phoenix Life Sciences International Limited Breaks Ground for Network of Community Clinics and Dispensing Pharmacies for the Republic of Vanuatu	19-03-07	CI
Phoenix Life Sciences International Limited Joins Michael Gobel as Finance Advisor of Its Board of Directors	19-02-27	CI
Phoenix Life Sciences International Limited Appoints David Steinman as Vice President of Regulatory Affairs	19-02-01	CI
Phoenix Life Sciences International Limited Announces 2019 International Expansion Strategy	19-01-08	CI
Phoenix Life Sciences International Announces Angus Stewart as New Agriculture and Horticulture Senior Advisor	18-11-28	CI
Phoenix Life Sciences Receives Import Certificate for Cannabis Diabetes Drug from the Republic of Vanuatu	18-11-14	CI
Phoenix Life Sciences International Limited will Change its Ticker to PLSI from MJMD	18-11-02	CI
MediJane Holdings, Inc. has Changed its Name to Phoenix Life Sciences International Ltd	18-11-01	CI
Phoenix Life Sciences International Limited announced a financing transaction	18-10-31	CI
Phoenix Life Sciences International Limited acquired Phoenix Life Sciences International Limited in a reverse merger transaction.	18-09-23	CI

Chart Phoenix Life Sciences International Limited

Duration

Period

Chart Phoenix Life Sciences International Limited

More charts

Company Profile

Phoenix Life Sciences International Limited is a healthcare solutions company. The Company provides a range of healthcare services to help governments implement diabetes solutions and national healthcare programs. It is primarily engaged in the provision of diabetes management as part of its healthcare services program and approved Phoenix Metabolic rollout. It operates an integrated group of companies for the fulfillment of government-sponsored healthcare service programs, plant-based pharmaceutical production and ongoing research programs. Its healthcare service programs are designed to provide solutions to manage diabetes and other non-communicable diseases (NCD). It partners and produces plant-based pharmaceuticals to treat diabetes, pain, cancer, autoimmune diseases and anxiety and other conditions. Its products include Phoenix Metabolic, Phoenix Auto, Phoenix Calm, Phoenix Daytime, Phoenix Mood, Phoenix Neuro, Phoenix Onco, Phoenix Pain, Phoenix Relax and Phoenix Sleep.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+29.68%	681B
NOVO NORDISK A/S	+20.30%	556B
JOHNSON & JOHNSON	-4.35%	361B
MERCK & CO., INC.	+17.65%	325B
ABBVIE INC.	+3.77%	285B
ASTRAZENECA PLC	+14.34%	235B
NOVARTIS AG	+4.38%	199B
ROCHE HOLDING AG	-11.62%	189B
PFIZER, INC.	-3.79%	157B

Other Pharmaceuticals